EU's innovative medicines initiative homes in on efficacy and knowledge management
This article was originally published in Scrip
Efficacy and knowledge management are to be the focus of Europe's Innovative Medicines Initiative's €160 million second call for proposals, said Jonathon Knowles, IMI deputy chairman at a press conference on Monday.
You may also be interested in...
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.